Personalized Metastasis-Directed Therapy for Prostate Cancer with Imaging and Biopsy Boost
Official title: Quantifying and Personalizing the Clinical Benefit of Metastasis-Directed Therapy in Men with De Novo Oligometastatic Prostate Cancer
Funded at Case Western Reserve University · NIH-11411288 · Data updated 2026-11-12
A large North American trial will test whether targeted radiation to metastases helps men with a specific type of prostate cancer and uses biomarker tests and imaging to tailor treatment.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | September 14, 2021 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $528,809 |
| NIH project number | 5U01CA257638-04 |
| Project ID | NIH-11411288 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are men with de novo oligometastatic prostate cancer enrolled in the North American sub-study of STAMPEDE (Arm M) and willing to provide biospecimens and imaging data.
✕Less likely to help
Some men may not benefit from MDT or may experience side effects without improved survival.
What this research studies
This study enrolls men with de novo oligometastatic prostate cancer to a phase 3 randomized trial comparing metastasis-directed radiotherapy plus standard care versus standard care alone. Researchers will collect tissue and blood samples and advanced imaging to identify biomarkers that predict who benefits most. The project brings together experts in genomics, imaging, bioinformatics, and statistics to analyze biomarkers and radiomic data alongside clinical outcomes. Results could help doctors personalize MDT to those most likely to be cured or helped by treatment.
Why it matters
Potential benefit: If successful, the trial could identify which patients will gain the most from MDT and guide personalized treatment decisions.
How similar studies have gone: This is building on a large, landmark multi-arm trial approach with biomarker analyses; predictive biomarker discovery in MDT is an emerging but promising area.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Spratt, Daniel Eidelberg — Case Western Reserve University
- Study coordinator: Spratt, Daniel Eidelberg
Related research
Other NIH-funded projects on the same topics.
-
PMN-MDSCs in bone metastasis of prostate cancer
A study in people with advanced prostate cancer bone metastases is exploring how immune-suppressing cells in the bone environment may limit current therapies and how targeting them could help.
-
Understanding how prostate cancer spreads to bone and stays dormant
Researchers are studying how prostate cancer moves to bone, why it becomes deadly, and how some cancer cells lie dormant before potentially causing trouble.
-
Understanding how tumor neighbors help prostate cancer spread and resist therapy
Researchers are studying how the tumor environment around prostate cancer cells promotes spread and resistance to common therapies, with a focus on a protein called ASPN.
-
Lipoylation and bone metastasis in prostate cancer: paving the way for new treatments
A study in men with advanced prostate cancer will explore how a chemical process called lipoylation influences cancer spreading to bone and whether this could lead to new therapies.
-
RIPK2/MKK7/c-Myc Signals as a Target to Stop Prostate Cancer from Spreading
This grant tests a new way to stop prostate cancer from spreading by blocking a signaling pathway involving RIPK2, MKK7, and c-Myc.
-
Understanding how prostate cancer spreads to bone and why it likes bone
A major NIH grant is funding research to uncover why prostate cancer cells spread to bone and how they grow there, using a mouse model that mirrors human bone metastasis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.